F100

Fluspirilen

• Synonym(e): 8-[4,4-Bis-(4-fluorphenyl)-butyl]-1-phenyl-1,3,8-triazino[4.5]decan-4-on, R 6218
• Empirische Formel (Hill-System): C₂₉H₃₁F₂N₃O
• CAS-Nummer: 1841-19-6
• Molekulargewicht: 475.57
• EG-Nummer: 217-418-6
• MDL-Nummer: MFCD00055137
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 24277915
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: solid
• Farbe: white
• Löslichkeit: DMSO: ≥20 mg/mL; H₂O: insoluble; ethanol: soluble
• Ersteller: Johnson & Johnson
• Lagertemp.: room temp
• SMILES String: Fc1ccc(cc1)C(CCCN2CCC3(CC2)N(CNC3=O)c4ccccc4)c5ccc(F)cc5
• InChI: 1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)
• InChIKey: QOYHHIBFXOOADH-UHFFFAOYSA-N
• Angaben zum Gen: human ... DRD1(1812) , DRD2(1813) , DRD3(1814) , DRD4(1815) , DRD5(1816)

Beschreibung

Anwendung

Fluspirilene has been used as a neuroleptic drug to study its effects on human ether-a-go-go related gene (HERG).[1]

Fluspirilene has been used to study its cytotoxicity effect on malignant glioma.[2]

Biochem./physiol. Wirkung

Fluspirilene has a potential to inhibit the activity of cyclin-dependent kinase 2 (CDK2). It is an effective anti-cancer agent used for treating human hepatocellular carcinoma.[3]

Fluspirilene is a dopamine receptor antagonist.[4] It also acts as a calcium channel blocker.[5] Fluspirilene is an antipsychotic agent and exhibits neuoleptic properties.[5][6] It exhibits therapeutic effects against glioblastoma and Schizophrenia.[6][1]

Leistungsmerkmale und Vorteile

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable
• Persönliche Schutzausrüstung: Eyeshields, Gloves, type N95 (US)